Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Cardiome Pharma Corp. : Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 09:03pm CEST

Vancouver, Canada, April 25, 2013 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has taken on responsibility for worldwide sales, marketing, and promotion of BRINAVESS™ (vernakalant IV) pursuant to a Transition Agreement signed with Merck, known as MSD outside the United States and Canada.  Under the agreement, worldwide sales and marketing rights will transfer to Cardiome immediately.  Pursuant to this agreement, Cardiome will continue to receive relevant royalties on worldwide sales.  Cardiome will also receive an undisclosed promotional services fee.  Regulatory product rights and product distribution responsibility are expected to transfer to Cardiome on or about July 15, 2013, following which Cardiome will recognize all BRINAVESS™ revenue and Merck will cease paying royalties or any promotional services fee.  Merck will either terminate or transfer Sponsor responsibility for each relevant clinical study to Cardiome by September 15, 2013. 

"Executing this transition agreement with Merck and commencing direct worldwide commercial sales activities in support of BRINAVESS™, ahead of schedule, is a critical milestone in Cardiome's history," stated William Hunter, M.D., President and CEO of Cardiome. "Outreach activities to physicians and caregivers who rely on BRINAVESS™ have resumed in select countries, which will enable us to gain valuable insight and experience in treating patients and help ensure a smooth transition of the product."

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer 
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

For Further Information:
Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email: ir@cardiome.com

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDIOME PHARMA CORP
08/16 CARDIOME PHARMA : Announces Recent Insider Purchases
08/09 CARDIOME PHARMA : Announces XYDALBA(TM) Single Dose Infusion Approval by Europea..
08/09 CARDIOME PHARMA : Reports Second Quarter 2016 Financial Results
08/08 CARDIOME PHARMA : Announces the Addition of Two Key Members to its Management Te..
08/03 CARDIOME PHARMA : to Hold Second Quarter 2016 Financial Results Conference Call ..
07/29 CARDIOME PHARMA : Closes Public Offering of 11,500,000 Common Shares
07/26 CARDIOME PHARMA : Announces Pricing of Public Offering of 10,000,000 Common Shar..
07/25 CARDIOME PHARMA : Announces Proposed Public Offering of Common Shares
07/18 CARDIOME PHARMA : Veritas Provides Investor Update
07/14 CARDIOME PHARMA : ESMOCARD® and ESMOCARD LYO® receive pricing approval and reimb..
More news
Sector news : Biopharmaceuticals
05:46p FTSE retreats as pharma stocks fall
03:56pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:12pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting
03:11pDJStocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 3rd Update
02:15pDJMylan Boosts Price Assistance for EpiPen Amid Backlash
More sector news : Biopharmaceuticals
News from SeekingAlpha
08/10 Cardiome Pharma's (CRME) CEO Bill Hunter on Q2 2016 Results - Earnings Call T..
08/10 Single-dose regimen for Cardiome's Xydalba OK'd in Europe
08/09 Cardiome Pharma misses by $0.18, misses on revenue
08/08 Notable earnings after Tuesday?s close
07/26 FINANCIALS - TOP 5 GAINERS / LOSERS : 00 pm
Advertisement
Financials ( CAD)
Sales 2016 34,0 M
EBIT 2016 -21,4 M
Net income 2016 -25,0 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 2,39x
Capi. / Sales 2017 1,82x
Capitalization 81,3 M
More Financials
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 183%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Harold H. Shlevin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP-62.22%63
CSL LIMITED4.56%38 411
ALEXION PHARMACEUTICAL..-30.74%29 628
GRIFOLS SA-8.75%13 683
BEIJING TIANTAN BIOLOG..15.03%3 069
JIANGXI BOYA BIO-PHARM..--.--%2 706
More Results